rised plant and machinery installed by Glaxo, Fairdeal Corporation, German Remedies, Bayer, Pfizer, Burroughs Welcome, Hoechst, Abbott and S.G. Pharmaceuticals has been submitted by the Technical Team; if so, when each report was submitted;

(b) whether final decision has been taken on each report; if so, what are the details thereof and when the same will be laid on the table of the House;

(c) whether it is a fact that all the locations of units of each company were not inspected; if so, the reasons therefor; and

(d) what was the value of plant and mahinery proposed for each project by each company, what was the value when the team visited and what were the major plants and machinery added in the meantime?

THE MINISTER OF CHEMICALS AND FERTILIZERS (SHRI VEERENDRA PATIL): (a) to (d) In 1984-85, on the spot verification of installation of plant and machinery were taken up in respect of all the companies referred to in the question except M/s. German Ramedies. In the case of M/s. Fairdeal Corporation of India Limited final view was taken that there was no case of infraction of Industries (Development & Regulation) Act. The reports in other cases are being processed.

Shortage of Anti-T.B. Drug

2244. SHRI SURESH PACHOURI: Will the Minister of CHEMICALS AND FERTILIZERS be pleased to state:

(a) whether B1-Teben tablets used by TB patients, manufactured by Bayer is not available in the market;

(b) what was the production of these tablets during 1979-80 and 1984-85;

(c) what is the price fixed for each pack of these tablets;

(d) whether it is a fact that the company is concentrating more on the production of non-essential items such as Bayers Tonic; Campoferron liquid, Edinol Capsules, Multibay Capsules and liquid;

(e) if so what was the sales turnover of each of these products during the last five years, year-wise, as well as that of B1-Teben tablets during the same period;

(f) what is the price fixed for each of these products and at what price each one is being sold; and

(g) what is the total sales turnover of the Company and the percentage sale of each of the vitamin preparation during the last three years, year-wise?

THE MINISTER OF CHEMICALS AND FERTILIZERS (SHRI VEERENDRA PATIL): (a) No, Sir. No shortage of B1-Teben tablets has been reported.

(b) Details are being collected and would be laid on the Table of the Rajya Sabha.

(c) The prices fixed for 2 packs of B1-Teben tablets are given below:—

		Rs.
B1-Teben Tabs	100's	4.97
	1000's	37.66

(d) to (g) Information to the extent available would be collected and laid on the Table of the Rajya Sabha.

Formulators of Gentamycin

2245. SHRI SYED REHMAT ALI: Will the Minister of CHMICALS AND FERTILIZERS be pleased to refer to answer to Unstarred Question 692 given in the Rajya Sabha on the 29th July, 1985 and state:

(a) names of formulators of Gentamycin to whom notices were issued and date of issuance;

(b) names of the companies in whose favour claims were worked out;

(c) whether it is a fact that the total claim runs into crores only on this drug;

(d) if so, by when the amount will be collected;

(e) whether it is a fact that imported Gentamycin is available at Rs. 18 per gram in open market;

(f) if so, by when further reduction will be done;

(g) what was the sales turnover of Gentamycin formulations of Fulford, Lyka, Nicholas and Biochem during the last three years, year-wise;

(h) what was the net profit, pretax profit, net worth and capital employed in respect of each company during the last three years, year-wise; and

(i) whether it is also a fact that claim notices of other drugs have also been sent to these companies; and if so, the details thereof, indicating the name of the companies, the drugs and the amount?

THE MINISTER OF CHEMICALS AND FERTILIZERS (SHRI VEERENDRA PATIL): (a) A Statement showing the names of the formulators of Gentamycin who have been issued notices under Drugs (Prices Control) Order, 1979 for recovery and credit into the Drug Prices Equalisation Account is attached.

(b) Amount due in case of companies like M|s. Fulford India Ltd., M|s. Nicholas Labs. (I) Ltd., M|s. Lyka Labs. (P) Ltd. and M|s. Biochem Pharms Ind. have been worked out.

(c) and (d) The process of recovery is on in accordance with due procedure of Law.

(e) to (h) Information to the extent available would be collected and laid on the Table of the Rajya Sabha.

(i) Names of other drugs in respect of which these companies have been issued notices for recovery, if any, are specified in Rajya Sabha Unstarred Question No. 1844 answered on 12-8-1985.

Statement

Sl. No.	Name of the Company	Date of issuing the notice
1	M/s. Fulford India Ltd.	31-5-1984
2	M/s Nicholas Labs . .	31-5-1984
3	M/s Standard Pharmaceuticals	31-5-1984
4	M/s. Pharmaceuticals Company of India . . .	31-5-1984
5	M/s. Lyka Labs. . .	31-5-1984
6	M/s. Biochem Pharmaceuticals . . .	31-5-1984

Earnings from wrong dialing

2246. SHRI PARVATHANENI UPENDRA:
SHRI GHULAM RASOOL MATTO:

Will the Minister of COMMUNICATIONS be pleased to state:

(a) whether Government are aware that it earns a substantial amount every year from "wrong telephone numbers" dialled due to defects in the telephone system;

(b) if so, what are the details of the amount earned on this account during 1982-83, 1983-84 and 1984-85;

(c) whether Government are considering to give any financial relief to the subscribers, while billing, on this account;

(d) whether Government are carrying out a study to arrive at the causes of this; and

(e) if so, what are the details thereof and the remedial measures proposed by Government to save the sub-